1. Dongari-Bagtzoglou AI, Ebersole JL. Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. J Periodontal Res. 1996. 31:90–98.
Article
2. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993. 4:197–250.
Article
3. Birkedal-Hansen H. Role of cytokine and inflammatory mediators in tissue destruction. J Periodontal Res. 1993. 28:500–510.
4. Ryan ME, Ramamurthy NS, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol. 1996. 3:85–96.
5. Newman HN. Modes of application of anti-plaque chemicals. J Clin Periodontol. 1986. 13:965–974.
Article
6. Greenstein G. Local drug delivery in the treatment of periodontal diseases: Assessing the clinical significance of the results. J Periodontol. 2006. 77:565–578.
Article
7. Reynolds H, Mashimo P, Slot J, et al. Use of tetracycline in the treatment of periodontitis. II. Microbiological studies. J Dent Res. 1978. 57:267.
8. Slots J, Rams TE. Antibiotics in periodontal therapy: Advantages and disadvantages. J Clin Periodontol. 1990. 17:479–493.
Article
9. Heijl L, Dahlen G, Sundin Y, Wenader A, Goodson JM. A 4-quadrant comparative study of periodontal treatment using tetracycline containing drug delivery fibers and scaling. J Clin Periodontol. 1991. 18:111–116.
Article
10. Olsvik B, Tenover F. Tetracycline resistance in periodontal pathogens. Clin Infecta Dis. 1993. 16:Suppl. 4. 310–323.
Article
11. Lee JY, Lee YM, Shin SY, et al. Effect of subantimicrobial dose doxycycline as an effective adjunct to scaling and root planing. J Periodontol. 2004. 75:1500–1508.
Article
12. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res. 1985. 20:12–23.
Article
13. Golub LM, Ciancio SG, Ramamurthy NS, Leung M, McNamara TF. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res. 1990. 25:321–330.
Article
14. Golub LM, McNamara TF, Ryan ME. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol. 2001. 28:146–156.
Article
15. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil(PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995. 22:100–109.
Article
16. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999. 42:1140–1146.
Article
17. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000. 71:1472–1483.
Article
18. Thomas JG, Metheny RJ, Karakiozis JM, Wetzel JM, Crout RJ. Long-term sub-antimicrobial doxycycline(Periostat) as adjunctive management in adult periodontitis: effects on subgingival bacterial population dynamics. Adv Dent Res. 1998. 12:32–39.
Article
19. Kim YS, Paik JW, Kim CS, Choi SH, Kim CK. Clinical effect of the subantimicrobial dose of doxycycline(SDD) on the chronic periodontitis. J Korean Acad Periodontol. 2002. 32:415–425.
Article
20. Position paper. Systemic antibiotics in periodontics. J Periodontol. 2004. 75:1553–1565.
21. Ashimoto A, Chen C, Bakker I, Slots J. Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol. 1996. 11:266–273.
Article
22. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Carranza's Clinical Periodontology. 2006. 10th ed. Philadelphia: W.B. Saunders;813–827.
23. Howell TH, Williams RC. Nonsteroidal antiinflammatory drugs as inhibitors of periodontal disease progression. Crit Rev Oral Biol Med. 1993. 4:177–196.
Article
24. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol. 1993. 64:Suppl. 5. 432–444.
Article
25. Williams RC, Jeffcoat MK, Howell TH, et al. Three year trial of flurbiprofen treatment in humans: post-treatment period. J Dent Res. 1991. 70:468.
26. Jeong SN, Han SB. The effects of low dose doxycycline regimen on gingival crevicular fluid enzyme activity of diabetic patients with periodontitis and adult periodontitis patients. J Korean Acad Periodontol. 1997. 27:701–722.
Article
27. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol. 2000. 71:521–532.
Article
28. Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res. 1998. 12:27–31.
Article
29. Genco RJ. Host responses in periodontal diseases: current concepts. J Periodontol. 1992. 63:Suppl. 4. 338–355.
Article
30. Badersten A, Nilvéus R, Egelberg J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. J Clin Periodontol. 1981. 8:57–72.
Article
31. Socransky SS, Smith C, Martin L, et al. "Checkerboard" DNA-DNA hybridization. Biotechniques. 1994. 17:788–792.